Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Monika Manne"'
Autor:
Dean Lee, Monika Manne, Roshan Kumar, Rebecca Silver, Alexandra Staskus, Julianna Crivello, Zhiyuan Wang, Dohyun Lee, Ross Fulton, Zhizhan Gu, Christos Hatzis, Francisco Adrian, Andreas Raue, Liang Schweizer
Publikováno v:
Cancer Research. 82:618-618
The discovery of predictive biomarkers of response is critical for forecasting patient benefit from novel immune-modulatory therapeutics. However, their discovery is hindered by the complexity of the drug modes of action and the lack of adequate biol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5805bf9f8fe23c7c6e2c22a2b918a4ef
https://doi.org/10.1158/1538-7445.am2022-618
https://doi.org/10.1158/1538-7445.am2022-618
Autor:
Sami Ellouze, Charina Ortega, Wenhua Xu, Xing Cai, Alexandra Staskus, Zhiyuan Wang, Jinping Gan, Liang Schweizer, Zachary Duda, Carine George, Sophie Foulon, Rebecca Silver, Juliana Crivello, Nicola Beltraminelli, Francisco Adrian, Shuo Wei, Jennifer Watkins-Yoon, Andreas Raue, Qian Zhang, Yun-Yueh Lu, Dean Lee, Mingjie Chen, Monika Manne, Ross B. Fulton, He Zhou
Publikováno v:
Cancer Research. 81:1883-1883
Despite the success of immune check point inhibition, identification of other pathways capable of modulating the immune response against the tumor remains challenging. T-cell co-stimulation has been investigated with limited clinical success so far d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e6c058abdcacdc8caa41b46975b01f7
https://doi.org/10.1158/1538-7445.am2021-1883
https://doi.org/10.1158/1538-7445.am2021-1883
Autor:
Ross B. Fulton, Zhiyuan Wang, Rebecca Silver, Ruina Jin, Joyce Pi, Jinping Gan, Zachery Duda, Andreas Raue, Monika Manne, Yuan Wang, Hongkai Zhang, Wenhua Xu, Xing Cai, Francisco Adrian, Carine George, Yun-Yueh Lu, Sophie Foulon, Sami Ellouze, Dean Lee, Charina Ortega, Robert Petit, Liang Schweizer, Julianna Crivello, Alexandra Staskus, Nicola Beltraminelli
Publikováno v:
Cancer Research. 81:1882-1882
Agonist OX40 antibodies have shown promising pre-clinical activities, but their clinical activities have been limited thus far. Several reasons may account for this limited clinical activity, including sub-optimal antibody design, dose selection, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a0247919e93d114469057acd96fed0d
https://doi.org/10.1158/1538-7445.am2021-1882
https://doi.org/10.1158/1538-7445.am2021-1882
Autor:
Ross B. Fulton, Julianna Crivello, Francisco Adrian, Zachary Duda, Dean Lee, Charina Ortega, Roshan Kumar, Liang Schweizer, Matt Delince, Monika Manne, Andreas Raue, Alexandra Staskus
Publikováno v:
Cancer Research. 80:PO-048
Immunomodulatory antibodies such as checkpoint inhibitors are showing very promising results in the clinic, but only a minority of patients respond to treatment and it is still challenging to identify these subpopulations. Prospective identification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d65157bf7e480f2592feb7b5359ce53
https://doi.org/10.1158/1538-7445.tumhet2020-po-048
https://doi.org/10.1158/1538-7445.tumhet2020-po-048